logo
Plus   Neg
Share
Email

Bayer Buys Gene Therapy Firm Asklepios BioPharma For $2 Bln Upfront Payment

Bayer AG (BAYZF.PK,BAYRY.PK,BYR.L) announced Monday the acquisition of Asklepios BioPharmaceutical, Inc. or AskBio, a US-based biopharmaceutical company.

Under the deal terms, Bayer will pay an upfront consideration of $2 billion and potential success-based milestone payments of up to $2 billion.

Some 75 percent of the potential success-based milestone payments are expected to be due during the course of the next five years and the remaining amount late thereafter.

The transaction is expected to close during the fourth quarter of 2020, subject to customary closing conditions, including receipt of the required regulatory approvals.

AskBio is a privately held, clinical-stage gene therapy company, and is specialized in the research, development and manufacturing of gene therapies across different therapeutic areas. Its development portfolio includes investigational pre-clinical and clinical stage candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases.

With the acquisition, Bayer will own full rights to AskBio's gene therapy platform, including a broad intellectual property portfolio and an established contract development and manufacturing organization laying the foundation for future partnerships in the area of adeno-associated virus therapies.

Bayer said the acquisition fuels its cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet need. The deal also complements its 2019 acquisition of BlueRock Therapeutics.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test. AstraZeneca's one batch of Covid vaccine has been suspended by Austrian health authorities following reports of a death and an illness after receiving vaccination, reports said. The issues were reported in the district clinic of Zwettl in Lower Austria province. The Federal Office for Safety in Health Care in the country said the remaining stocks of the affected AstraZeneca/Oxford Covid-19 vaccine DuPont (DD) announced Monday that it has agreed to acquire Laird Performance Materials from with private equity firm Advent International for $2.3 billion. The company will use existing cash balances for the acquisition. The transaction is expected to close in the third quarter of 2021, subject to regulatory...
Follow RTT